Overview
- Lilly on Wednesday released topline 80‑week TRANSCEND‑T2D‑2 results showing retatrutide 9 mg and 12 mg lowered A1C by 2.2 percentage points compared with 1.8 points for Ozempic 2 mg.
- Participants on retatrutide lost about 44.3 to 47.4 pounds on average versus about 20.9 pounds for Ozempic over 80 weeks, a roughly twofold difference reported by the company.
- Retatrutide targets three hormone receptors — GLP‑1, GIP and glucagon — a design intended to combine appetite suppression, stronger blood‑sugar control and increased calorie burning.
- The drug produced more gastrointestinal side effects and higher treatment discontinuation rates than Ozempic, and Lilly says the findings are preliminary until full peer‑reviewed data are published.
- Lilly plans an FDA submission in early 2027 but the near‑term public‑health picture is complicated by unauthorized gray‑market products and FDA warnings after reports of serious adverse events.